Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5′-methylthioadenosine phosphorylase

Indranil Basu, Joseph Locker, Maria B. Cassera, Thomas J. Belbin, Emilio F. Merino, Xinyuan Dong, Ivan Hemeon, Gary B. Evans, Chandan Guha, Vern L. Schramm

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The S-adenosylmethionine (AdoMet) salvage enzyme 5′- methylthioadenosine phosphorylase (MTAP) has been implicated as both a cancer target and a tumor suppressor. We tested these hypotheses in mouse xenografts of human lung cancers. AdoMet recycling from 5′-methylthioadenosine (MTA) was blocked by inhibition of MTAP with methylthio-DADMe-Immucillin-A (MTDIA), an orally available, nontoxic, picomolar transition state analogue. Blood, urine, and tumor levels of MTA increased in response to MTDIA treatment. MTDIA treatment inhibited A549 (human non-small cell lung carcinoma) and H358 (human bronchioloalveolar non-small cell lung carcinoma cells) xenograft tumor growth in immunodeficient Rag2-/-γC-/- and NCr-nu mice. Systemic MTA accumulation is implicated as the tumor-suppressive metabolite because MTDIA is effective for in vivo treatment of A549 MTAP-/- and H358 MTAP+/+ tumors. Tumors from treated mice showed increased MTA and decreased polyamines but little alteration in AdoMet, methionine, or adenine levels. Gene expression profiles of A549 tumors from treated and untreated mice revealed only modest alterations with 62 up-regulated and 63 down-regulated mRNAs (≥3-fold). MTDIA antitumor activity in xenografts supports MTAP as a target for lung cancer therapy.

Original languageEnglish (US)
Pages (from-to)4902-4911
Number of pages10
JournalJournal of Biological Chemistry
Volume286
Issue number6
DOIs
StatePublished - Feb 11 2011

Fingerprint

Heterografts
Tumors
Lung Neoplasms
Neoplasm Metastasis
S-Adenosylmethionine
Growth
Neoplasms
Cells
Non-Small Cell Lung Carcinoma
Salvaging
Polyamines
Adenine
Metabolites
5'-methylthioadenosine phosphorylase
Gene expression
Recycling
Methionine
Transcriptome
Blood
methylthio-DADMe-immucillin-A

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Medicine(all)

Cite this

Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5′-methylthioadenosine phosphorylase. / Basu, Indranil; Locker, Joseph; Cassera, Maria B.; Belbin, Thomas J.; Merino, Emilio F.; Dong, Xinyuan; Hemeon, Ivan; Evans, Gary B.; Guha, Chandan; Schramm, Vern L.

In: Journal of Biological Chemistry, Vol. 286, No. 6, 11.02.2011, p. 4902-4911.

Research output: Contribution to journalArticle

Basu, Indranil ; Locker, Joseph ; Cassera, Maria B. ; Belbin, Thomas J. ; Merino, Emilio F. ; Dong, Xinyuan ; Hemeon, Ivan ; Evans, Gary B. ; Guha, Chandan ; Schramm, Vern L. / Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5′-methylthioadenosine phosphorylase. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 6. pp. 4902-4911.
@article{d7784e4864134d52935bf7ed84819c9c,
title = "Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5′-methylthioadenosine phosphorylase",
abstract = "The S-adenosylmethionine (AdoMet) salvage enzyme 5′- methylthioadenosine phosphorylase (MTAP) has been implicated as both a cancer target and a tumor suppressor. We tested these hypotheses in mouse xenografts of human lung cancers. AdoMet recycling from 5′-methylthioadenosine (MTA) was blocked by inhibition of MTAP with methylthio-DADMe-Immucillin-A (MTDIA), an orally available, nontoxic, picomolar transition state analogue. Blood, urine, and tumor levels of MTA increased in response to MTDIA treatment. MTDIA treatment inhibited A549 (human non-small cell lung carcinoma) and H358 (human bronchioloalveolar non-small cell lung carcinoma cells) xenograft tumor growth in immunodeficient Rag2-/-γC-/- and NCr-nu mice. Systemic MTA accumulation is implicated as the tumor-suppressive metabolite because MTDIA is effective for in vivo treatment of A549 MTAP-/- and H358 MTAP+/+ tumors. Tumors from treated mice showed increased MTA and decreased polyamines but little alteration in AdoMet, methionine, or adenine levels. Gene expression profiles of A549 tumors from treated and untreated mice revealed only modest alterations with 62 up-regulated and 63 down-regulated mRNAs (≥3-fold). MTDIA antitumor activity in xenografts supports MTAP as a target for lung cancer therapy.",
author = "Indranil Basu and Joseph Locker and Cassera, {Maria B.} and Belbin, {Thomas J.} and Merino, {Emilio F.} and Xinyuan Dong and Ivan Hemeon and Evans, {Gary B.} and Chandan Guha and Schramm, {Vern L.}",
year = "2011",
month = "2",
day = "11",
doi = "10.1074/jbc.M110.198374",
language = "English (US)",
volume = "286",
pages = "4902--4911",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "6",

}

TY - JOUR

T1 - Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5′-methylthioadenosine phosphorylase

AU - Basu, Indranil

AU - Locker, Joseph

AU - Cassera, Maria B.

AU - Belbin, Thomas J.

AU - Merino, Emilio F.

AU - Dong, Xinyuan

AU - Hemeon, Ivan

AU - Evans, Gary B.

AU - Guha, Chandan

AU - Schramm, Vern L.

PY - 2011/2/11

Y1 - 2011/2/11

N2 - The S-adenosylmethionine (AdoMet) salvage enzyme 5′- methylthioadenosine phosphorylase (MTAP) has been implicated as both a cancer target and a tumor suppressor. We tested these hypotheses in mouse xenografts of human lung cancers. AdoMet recycling from 5′-methylthioadenosine (MTA) was blocked by inhibition of MTAP with methylthio-DADMe-Immucillin-A (MTDIA), an orally available, nontoxic, picomolar transition state analogue. Blood, urine, and tumor levels of MTA increased in response to MTDIA treatment. MTDIA treatment inhibited A549 (human non-small cell lung carcinoma) and H358 (human bronchioloalveolar non-small cell lung carcinoma cells) xenograft tumor growth in immunodeficient Rag2-/-γC-/- and NCr-nu mice. Systemic MTA accumulation is implicated as the tumor-suppressive metabolite because MTDIA is effective for in vivo treatment of A549 MTAP-/- and H358 MTAP+/+ tumors. Tumors from treated mice showed increased MTA and decreased polyamines but little alteration in AdoMet, methionine, or adenine levels. Gene expression profiles of A549 tumors from treated and untreated mice revealed only modest alterations with 62 up-regulated and 63 down-regulated mRNAs (≥3-fold). MTDIA antitumor activity in xenografts supports MTAP as a target for lung cancer therapy.

AB - The S-adenosylmethionine (AdoMet) salvage enzyme 5′- methylthioadenosine phosphorylase (MTAP) has been implicated as both a cancer target and a tumor suppressor. We tested these hypotheses in mouse xenografts of human lung cancers. AdoMet recycling from 5′-methylthioadenosine (MTA) was blocked by inhibition of MTAP with methylthio-DADMe-Immucillin-A (MTDIA), an orally available, nontoxic, picomolar transition state analogue. Blood, urine, and tumor levels of MTA increased in response to MTDIA treatment. MTDIA treatment inhibited A549 (human non-small cell lung carcinoma) and H358 (human bronchioloalveolar non-small cell lung carcinoma cells) xenograft tumor growth in immunodeficient Rag2-/-γC-/- and NCr-nu mice. Systemic MTA accumulation is implicated as the tumor-suppressive metabolite because MTDIA is effective for in vivo treatment of A549 MTAP-/- and H358 MTAP+/+ tumors. Tumors from treated mice showed increased MTA and decreased polyamines but little alteration in AdoMet, methionine, or adenine levels. Gene expression profiles of A549 tumors from treated and untreated mice revealed only modest alterations with 62 up-regulated and 63 down-regulated mRNAs (≥3-fold). MTDIA antitumor activity in xenografts supports MTAP as a target for lung cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=79953000186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953000186&partnerID=8YFLogxK

U2 - 10.1074/jbc.M110.198374

DO - 10.1074/jbc.M110.198374

M3 - Article

C2 - 21135097

AN - SCOPUS:79953000186

VL - 286

SP - 4902

EP - 4911

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 6

ER -